Profile
AGRX ZTS TAK HLN TEVA NBIX
Company Name Agile Therapeutics, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $10.01M $82.06B $43.45B $42.15B $19.37B $14.77B
Employees 0.02K 14.10K 49.28K 25.41K 35.00K 1.45K
CEO Mr. Alfred F. Altomari Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Kevin C. Gorman Ph.D.
Ratings
AGRX ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 3 2 3 1 3
Quant Rating Sell Neutral Sell Neutral Strong Sell Neutral
Trading
AGRX ZTS TAK HLN TEVA NBIX
Last Close $1.45 $179.84 $13.77 $9.23 $17.1 $146.8
High 52 $2.93 $200.09 $16.32 $9.23 $17.4 $147.46
Low 52 $0.27 $145.54 $12.6 $7.78 $8.12 $101.19
Price vs. 52 Week High -50.51 % -10.12 % -15.63 % 0 % -1.72 % -0.45 %
Price vs. 52 Week Low 437.04 % 23.57 % 9.29 % 18.64 % 110.59 % 45.07 %
Total Return
AGRX ZTS TAK HLN TEVA NBIX
1 Month Return 1.4 % 1.92 % 6.66 % 9.49 % 5.17 % 9.3 %
3 Month Return 262.5 % 13.52 % 5.68 % 9.23 % 23.82 % 7.95 %
6 Month Return -8.23 % -6.1 % -5.68 % 12.97 % 43.58 % 3.27 %
9 Month Return -17.14 % 15.26 % 2.27 % 18.49 % 110.59 % 38.4 %
YTD Return -25.64 % -8.88 % -3.5 % 12.15 % 63.79 % 11.41 %
1 Year Return -44.76 % -4.69 % -11.79 % 6.28 % 103.09 % 44.99 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AGRX ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 0.93 % 4.08 % 2.12 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.76 % 0.92 % - 3.3 % 20.82 %
Dividend Per Share (TTM) - 1.67 % 0.56 % 0.15 % - -
Payout Ratio (TTM) - 29.95 % 199.34 % - - -
Growth
AGRX ZTS TAK HLN TEVA NBIX
Asset Growth -27.99 % -4.28 % 8.25 % -2.18 % -1.2 % 37.27 %
Gross Profit Growth 162.23 % 3.7 % -16.6 % 5.85 % 9.64 % 26.06 %
Revenue Growth 80.02 % 5.74 % 5.87 % 4.09 % 6.16 % 26.76 %
Revenue 3 Year -48.64 % 31.98 % 33.13 % 13.9 % -6.92 % 71.93 %
Revenue 5 Year - 53.64 % 149.89 % 32.87 % -23.33 % 308.36 %
Revenue 10 Year - 103.1 % 154.38 % 32.87 % -40.82 % 44100.16 %
EBIT Growth 52.01 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Net Income Growth 43.08 % 10.88 % -54.56 % -1.04 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share 99.48 % 47.55 % -61.74 % -8.67 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share 99.42 % 71.94 % 62.27 % 59.66 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share 99.79 % 404.24 % 36.33 % 59.66 % -133.42 % 470.4 %
Operating Income Growth 52.01 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) 73.36 % 23.06 % -34.47 % -16.48 % -13.96 % 14.88 %
Operating 3 Year CFG 99.6 % 14.12 % -36.76 % 22.08 % 10.09 % 62.6 %
Operating 5 Year CFG 99.55 % 37.69 % 139.61 % 118.54 % -48.98 % 275.6 %
Operating 10 Year CFG 99.85 % 274.61 % 335.67 % 118.54 % -67.94 % 1000.37 %
EPS Growth 88.59 % 12.64 % -54.92 % - 76.42 % 59.01 %
EPS Diluted Growth 88.59 % 12.92 % -54.86 % - 76.42 % 58.33 %
Book Value Per Share 41.02 % 15.34 % 13.54 % 1.38 % -5.72 % 28.15 %
Share Holder 3 Year Equity Growth Per Share -100.65 % 36.7 % 40.38 % -36.6 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share -100.64 % 139.55 % 73.27 % -39.41 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share 99.95 % 476.36 % 197.1 % -39.41 % -74.76 % 1167.34 %
Dividend Per Share Growth - 15.15 % 1.95 % -85.58 % - -
Dividend 3 Year Growth Per Share - 87.76 % 1.19 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % - -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 103.93 % -66.42 % -100 % -
Debt Growth -1.76 % -15.91 % 24.67 % -9.43 % -6.53 % 62.95 %
Free Cash Flow Growth 73.46 % 22.25 % -53.54 % -20.06 % -19.19 % 11.99 %
Updated On 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
AGRX ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 59.73 % 69.2 % 66.54 % 60.04 % 48.99 % 97.78 %
Return on Assets TTM -61.81 % 16.66 % 0.95 % - -1.15 % 10.65 %
Return on Equity TTM 60.92 % 48.41 % 2.06 % 6.53 % -6.86 % 17.45 %
Return on Capital Employed TTM 180.44 % 25.86 % 3.22 % - 3.75 % 17.05 %
Net Income Per EBT TTM 100 % 80.07 % 293.72 % 64.62 % 59.18 % 78.68 %
EBT Per Ebit TTM 48.91 % 92.82 % 11.92 % 82.52 % -76.63 % 99.89 %
EBIT Per Revenue TTM -74.13 % 36.83 % 9.65 % 18.08 % 6.79 % 23.73 %
Cash Flow To Debt Ratio TTM -2766.67 % 36.43 % 14.47 % - 8.57 % 118.01 %
Receivables Turnover TTM 4.47 6.75 6.11 - 4.63 4.4
Payables Turnover TTM 0.69 6.64 4.46 - 3.35 0.5
Inventory Turnover TTM 2.31 1.01 1.18 - 2.07 1.18
Fixed Asset Turnover TTM 5583.12 % 251.27 % 214.28 % - 267.75 % 572.67 %
Asset Turnover TTM 170.46 % 60.87 % 28.22 % - 37.45 % 57.08 %
Operating Cash Flow Per Share TTM -2.26 5.24 452.66 - 1.5 6.47
Free Cash Flow Per Share TTM -2.26 3.82 146.27 - 1.04 6.16
Cash Per Share TTM 56.46 % 431.22 % 29177.57 % 22.71 % 266.34 % 1213.03 %
Operating Cash Flow Sales Ratio TTM -48.65 % 27.47 % 16.66 % - 10.51 % 32.56 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 72.95 % 32.31 % - 69.66 % 95.2 %
Cash Flow Coverage Ratios TTM -2766.67 % 36.43 % 14.47 % - 8.57 % 118.01 %
Price To Free Cash Flows Ratio TTM -0.96 46.89 29.1 - 16.51 24.05
Price To Operating Cash Flows Ratio TTM -0.64 34.33 4.68 - 11.4 22.7
Price Cash Flow Ratio TTM -0.64 34.33 4.68 - 11.4 22.7
Income Statement (TTM)
AGRX ZTS TAK HLN TEVA NBIX
Revenue $0.02B $8.54B $4263.76B $11.3B $15.85B $1.89B
Gross Profit $0.01B $5.83B $2321.31B $6.96B $7.65B $1.85B
Gross Profit Ratio 54.18% 68.28% 54.44% 61.6% 48.25% 97.9%
EBITDA $-0.02B $3.56B $1254.52B $2.81B $4.27B $0.42B
Net Income $-0.01B $2.34B $144.07B $1.05B $-0.56B $0.25B
EPS Diluted -6.71 5.07 91.16 0.11 -0.5 2.47
Balance Sheet (MRQ)
AGRX ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $6.56B $4476.5B $8.8B $18.48B $0.26B
Total Liabilities $0.03B $9.3B $7834.79B $17.33B $35.35B $1.02B
Total Equity $-0.02B $4.99B $7274.01B $16.73B $8.13B $2.23B
Total Investments $0B $0.02B $683.22B $0.07B $0.01B $0.94B
Total Debt $0B $6.8B $5463.39B $9.46B $20.15B $0.43B
Total Assets $0.01B $14.29B $15108.79B $34.06B $43.48B $3.25B
Cash Flow Statement (TTM)
AGRX ZTS TAK HLN TEVA NBIX
Net Income $-0.01B $2.34B $144.07B $1.05B $-0.62B $0.25B
Inventory $-0B $-0.36B $-115.74B $-0.13B $-0.15B $0.01B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0.01B $2.35B $640.32B $1.72B $1.37B $0.39B
Capital Expenditure $0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.9
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AKAN Akanda Corp. 1.63
ALIM Alimera Sciences, Inc. 5.57
ALVO Alvotech 11.59
ALVOW Alvotech 2.59
AMPH Amphastar Pharmaceuticals, Inc. 42.48
AMRX Amneal Pharmaceuticals, Inc. 7.44
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 63.25
AQST Aquestive Therapeutics, Inc. 3.82
ASRT Assertio Holdings, Inc. 1.505
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 16.72
AYTU Aytu BioPharma, Inc. 2.7
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AGRX
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 119.77
VXF Vanguard Extended Market Index Fund 0 178.79
VQNPX Vanguard Growth and Income Fund 0 63.85
VGIAX Vanguard Quantitative Funds - Vanguard Growth and Income Fund 0 104.18
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 135.6
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 135.6
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
VEMPX Vanguard Extended Market Index InstlPlus 0 334.63
Unlock